 Samer Al Hadidi
Concepts (190)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 43 | 2025 | 3049 | 7.710 |
Why?
| | Hematologic Neoplasms | 6 | 2025 | 106 | 3.150 |
Why?
| | Immunotherapy, Adoptive | 10 | 2025 | 167 | 2.900 |
Why?
| | Antibodies, Bispecific | 6 | 2025 | 94 | 2.650 |
Why?
| | Hematopoietic Stem Cell Transplantation | 8 | 2025 | 606 | 2.630 |
Why?
| | Hematology | 4 | 2025 | 28 | 2.560 |
Why?
| | Medical Oncology | 6 | 2024 | 104 | 2.400 |
Why?
| | Clinical Trials as Topic | 7 | 2025 | 468 | 2.380 |
Why?
| | Neoplasms | 8 | 2024 | 1305 | 2.310 |
Why?
| | Hodgkin Disease | 3 | 2021 | 49 | 2.020 |
Why?
| | Drug Approval | 5 | 2024 | 46 | 1.880 |
Why?
| | Humans | 77 | 2025 | 52336 | 1.880 |
Why?
| | Neoplasm Recurrence, Local | 6 | 2024 | 643 | 1.840 |
Why?
| | Neutropenia | 2 | 2023 | 115 | 1.520 |
Why?
| | Waldenstrom Macroglobulinemia | 2 | 2022 | 40 | 1.470 |
Why?
| | Physicians | 3 | 2024 | 240 | 1.440 |
Why?
| | Transplantation, Autologous | 7 | 2024 | 488 | 1.370 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 1031 | 1.240 |
Why?
| | T-Lymphocytes | 6 | 2024 | 340 | 1.230 |
Why?
| | Neoplasms, Second Primary | 2 | 2024 | 77 | 1.050 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2024 | 37 | 1.020 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 1676 | 0.990 |
Why?
| | United States Food and Drug Administration | 6 | 2024 | 98 | 0.970 |
Why?
| | United States | 14 | 2025 | 5182 | 0.930 |
Why?
| | Receptors, G-Protein-Coupled | 2 | 2024 | 57 | 0.910 |
Why?
| | Authorship | 1 | 2024 | 12 | 0.890 |
Why?
| | Terminology as Topic | 2 | 2025 | 70 | 0.880 |
Why?
| | Autoimmune Diseases | 1 | 2025 | 86 | 0.860 |
Why?
| | Practice Guidelines as Topic | 2 | 2025 | 487 | 0.850 |
Why?
| | Antibodies, Monoclonal, Humanized | 3 | 2023 | 236 | 0.820 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2024 | 140 | 0.810 |
Why?
| | Awards and Prizes | 1 | 2023 | 18 | 0.800 |
Why?
| | Fractures, Spontaneous | 1 | 2022 | 15 | 0.790 |
Why?
| | Tomography, X-Ray Computed | 3 | 2017 | 1162 | 0.780 |
Why?
| | Thalidomide | 1 | 2024 | 377 | 0.760 |
Why?
| | Periodicals as Topic | 1 | 2022 | 61 | 0.760 |
Why?
| | Lymphoma, B-Cell | 1 | 2022 | 61 | 0.740 |
Why?
| | Patient Participation | 1 | 2022 | 69 | 0.720 |
Why?
| | Bone Diseases | 1 | 2022 | 95 | 0.720 |
Why?
| | Venous Thromboembolism | 1 | 2022 | 75 | 0.720 |
Why?
| | Antibodies, Monoclonal | 3 | 2024 | 481 | 0.700 |
Why?
| | Brain Diseases | 1 | 2021 | 79 | 0.700 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2020 | 41 | 0.680 |
Why?
| | Racism | 1 | 2021 | 61 | 0.650 |
Why?
| | Atrial Fibrillation | 1 | 2022 | 200 | 0.630 |
Why?
| | Quality of Life | 2 | 2022 | 868 | 0.620 |
Why?
| | Receptors, Antigen, T-Cell | 3 | 2024 | 55 | 0.600 |
Why?
| | Healthcare Disparities | 1 | 2022 | 299 | 0.600 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2025 | 125 | 0.590 |
Why?
| | Platinum Compounds | 1 | 2018 | 11 | 0.590 |
Why?
| | Mycosis Fungoides | 1 | 2018 | 27 | 0.570 |
Why?
| | Subclavian Artery | 1 | 2017 | 20 | 0.570 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 9 | 0.560 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2018 | 24 | 0.560 |
Why?
| | Antithrombin III Deficiency | 1 | 2017 | 2 | 0.560 |
Why?
| | Pruritus | 1 | 2018 | 45 | 0.560 |
Why?
| | Female | 16 | 2025 | 28105 | 0.560 |
Why?
| | Ulcer | 1 | 2017 | 25 | 0.550 |
Why?
| | Lymphoproliferative Disorders | 1 | 2017 | 27 | 0.550 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2017 | 33 | 0.540 |
Why?
| | Tachycardia, Ventricular | 1 | 2017 | 46 | 0.540 |
Why?
| | Combined Modality Therapy | 4 | 2024 | 636 | 0.540 |
Why?
| | Abdominal Pain | 1 | 2017 | 85 | 0.540 |
Why?
| | Thromboembolism | 1 | 2017 | 50 | 0.530 |
Why?
| | Colon | 1 | 2017 | 104 | 0.530 |
Why?
| | Deglutition Disorders | 1 | 2017 | 80 | 0.520 |
Why?
| | Adult | 12 | 2025 | 14139 | 0.520 |
Why?
| | Diagnosis, Differential | 5 | 2018 | 1044 | 0.510 |
Why?
| | Dexamethasone | 3 | 2024 | 440 | 0.510 |
Why?
| | Gangrene | 1 | 2016 | 14 | 0.500 |
Why?
| | Penile Diseases | 1 | 2016 | 16 | 0.490 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2018 | 170 | 0.490 |
Why?
| | Immunosuppressive Agents | 1 | 2017 | 243 | 0.490 |
Why?
| | Aspirin | 1 | 2016 | 115 | 0.480 |
Why?
| | Leiomyoma | 1 | 2015 | 23 | 0.470 |
Why?
| | Migraine with Aura | 1 | 2014 | 5 | 0.460 |
Why?
| | Hysterectomy | 1 | 2015 | 90 | 0.460 |
Why?
| | Plasma Cells | 3 | 2025 | 239 | 0.450 |
Why?
| | Edema | 1 | 2015 | 65 | 0.450 |
Why?
| | Early Diagnosis | 1 | 2014 | 87 | 0.450 |
Why?
| | Carotid Stenosis | 1 | 2014 | 66 | 0.440 |
Why?
| | Ovarian Neoplasms | 1 | 2018 | 459 | 0.430 |
Why?
| | Middle Aged | 9 | 2025 | 13014 | 0.430 |
Why?
| | Melphalan | 3 | 2023 | 181 | 0.410 |
Why?
| | Brain Ischemia | 1 | 2014 | 161 | 0.410 |
Why?
| | Skin Neoplasms | 1 | 2018 | 500 | 0.400 |
Why?
| | Immunotherapy | 2 | 2025 | 244 | 0.390 |
Why?
| | Risk Factors | 5 | 2025 | 3872 | 0.390 |
Why?
| | Prognosis | 5 | 2025 | 2094 | 0.380 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2015 | 187 | 0.380 |
Why?
| | Myeloid Differentiation Factor 88 | 2 | 2022 | 34 | 0.380 |
Why?
| | Antineoplastic Agents | 1 | 2020 | 1222 | 0.370 |
Why?
| | Lung Neoplasms | 1 | 2018 | 636 | 0.370 |
Why?
| | Treatment Outcome | 5 | 2025 | 5407 | 0.340 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2023 | 594 | 0.340 |
Why?
| | B-Cell Maturation Antigen | 4 | 2024 | 98 | 0.340 |
Why?
| | Male | 9 | 2025 | 26696 | 0.330 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2016 | 561 | 0.320 |
Why?
| | Stroke | 1 | 2014 | 509 | 0.320 |
Why?
| | Survival Analysis | 2 | 2023 | 671 | 0.300 |
Why?
| | Breast Neoplasms | 1 | 2018 | 1206 | 0.300 |
Why?
| | Pulmonary Emphysema | 1 | 2017 | 21 | 0.270 |
Why?
| | Conflict of Interest | 2 | 2024 | 26 | 0.270 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 327 | 0.270 |
Why?
| | Neoplasm, Residual | 3 | 2025 | 173 | 0.260 |
Why?
| | Tumor Microenvironment | 3 | 2023 | 255 | 0.260 |
Why?
| | Mutation | 2 | 2022 | 1351 | 0.250 |
Why?
| | Syndrome | 2 | 2021 | 247 | 0.240 |
Why?
| | Career Choice | 2 | 2024 | 116 | 0.240 |
Why?
| | Phthalimides | 1 | 2024 | 3 | 0.230 |
Why?
| | Diffusion Magnetic Resonance Imaging | 1 | 2025 | 133 | 0.230 |
Why?
| | Piperidones | 1 | 2024 | 7 | 0.230 |
Why?
| | Drug Industry | 1 | 2024 | 40 | 0.220 |
Why?
| | Morpholines | 1 | 2024 | 65 | 0.220 |
Why?
| | Disease Management | 1 | 2025 | 188 | 0.210 |
Why?
| | Positron-Emission Tomography | 1 | 2025 | 303 | 0.210 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2024 | 205 | 0.210 |
Why?
| | Disease Progression | 3 | 2025 | 870 | 0.210 |
Why?
| | Financing, Organized | 1 | 2023 | 14 | 0.200 |
Why?
| | Molecular Targeted Therapy | 1 | 2024 | 134 | 0.200 |
Why?
| | Fellowships and Scholarships | 1 | 2024 | 127 | 0.200 |
Why?
| | Societies, Medical | 1 | 2024 | 200 | 0.200 |
Why?
| | Health Facilities | 1 | 2023 | 40 | 0.200 |
Why?
| | Faculty | 1 | 2022 | 74 | 0.200 |
Why?
| | Certification | 1 | 2022 | 51 | 0.200 |
Why?
| | Patients | 1 | 2022 | 51 | 0.190 |
Why?
| | Geography | 1 | 2022 | 66 | 0.190 |
Why?
| | Aged | 4 | 2025 | 10109 | 0.190 |
Why?
| | Social Media | 1 | 2024 | 117 | 0.190 |
Why?
| | Paraproteinemias | 1 | 2022 | 74 | 0.190 |
Why?
| | Blood Coagulation | 1 | 2022 | 60 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2022 | 37 | 0.190 |
Why?
| | Animals | 4 | 2024 | 13523 | 0.190 |
Why?
| | Patient Selection | 1 | 2023 | 259 | 0.190 |
Why?
| | Transplantation Conditioning | 1 | 2022 | 93 | 0.190 |
Why?
| | Phenylalanine | 1 | 2022 | 132 | 0.180 |
Why?
| | Research Design | 1 | 2023 | 354 | 0.180 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 91 | 0.180 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 106 | 0.180 |
Why?
| | Pyrimidines | 1 | 2022 | 199 | 0.170 |
Why?
| | Maintenance Chemotherapy | 1 | 2020 | 51 | 0.170 |
Why?
| | Risk Assessment | 1 | 2025 | 1323 | 0.170 |
Why?
| | Protein Kinase Inhibitors | 1 | 2022 | 230 | 0.160 |
Why?
| | Pain | 1 | 2022 | 360 | 0.160 |
Why?
| | Anticoagulants | 1 | 2022 | 267 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2022 | 216 | 0.160 |
Why?
| | Minority Groups | 1 | 2020 | 135 | 0.160 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2268 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2018 | 124 | 0.140 |
Why?
| | Prospective Studies | 1 | 2023 | 2428 | 0.140 |
Why?
| | Vomiting | 1 | 2017 | 73 | 0.140 |
Why?
| | Aged, 80 and over | 2 | 2025 | 3391 | 0.130 |
Why?
| | Electrocardiography | 1 | 2017 | 267 | 0.120 |
Why?
| | Weight Loss | 1 | 2017 | 249 | 0.120 |
Why?
| | Carotid Artery, Internal | 1 | 2014 | 20 | 0.120 |
Why?
| | Endarterectomy, Carotid | 1 | 2014 | 62 | 0.110 |
Why?
| | Cerebral Angiography | 1 | 2014 | 87 | 0.110 |
Why?
| | Lower Extremity | 1 | 2015 | 99 | 0.110 |
Why?
| | Bone Marrow | 2 | 2022 | 364 | 0.080 |
Why?
| | Pregnancy | 1 | 2018 | 2675 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2025 | 1110 | 0.080 |
Why?
| | Young Adult | 1 | 2018 | 4319 | 0.070 |
Why?
| | Radiography, Thoracic | 1 | 2017 | 66 | 0.070 |
Why?
| | World Health Organization | 1 | 2025 | 58 | 0.060 |
Why?
| | ROC Curve | 1 | 2025 | 251 | 0.060 |
Why?
| | Equipment and Supplies | 1 | 2024 | 16 | 0.060 |
Why?
| | Marketing | 1 | 2024 | 22 | 0.060 |
Why?
| | Cystatin M | 1 | 2024 | 19 | 0.050 |
Why?
| | Disclosure | 1 | 2024 | 41 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 180 | 0.050 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.050 |
Why?
| | X-Ray Microtomography | 1 | 2024 | 79 | 0.050 |
Why?
| | Antibodies | 1 | 2024 | 152 | 0.050 |
Why?
| | Mice | 2 | 2024 | 5965 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 96 | 0.050 |
Why?
| | Chromosome Deletion | 1 | 2023 | 142 | 0.050 |
Why?
| | Transcriptome | 1 | 2025 | 367 | 0.050 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2023 | 263 | 0.050 |
Why?
| | Pharmaceutical Preparations | 1 | 2022 | 74 | 0.050 |
Why?
| | Disease-Free Survival | 1 | 2022 | 460 | 0.050 |
Why?
| | Bone Marrow Transplantation | 1 | 2022 | 113 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 297 | 0.050 |
Why?
| | Genomics | 1 | 2023 | 270 | 0.050 |
Why?
| | Proportional Hazards Models | 1 | 2022 | 443 | 0.050 |
Why?
| | Stem Cell Transplantation | 1 | 2022 | 185 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2021 | 105 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1436 | 0.040 |
Why?
| | Cohort Studies | 1 | 2023 | 1532 | 0.040 |
Why?
| | Recurrence | 1 | 2021 | 672 | 0.040 |
Why?
| | Retrospective Studies | 1 | 2025 | 6578 | 0.030 |
Why?
|
|
Al Hadidi's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|